Collectively, this study suggests that the HOXA5/AKT/p53 axis plays a crucial role in developing tamoxifen resistance and its associated phenotypes in ER+ breast cancer, and hence, could be considered as a potential therapeutic target for reversing tamoxifen resistance in breast cancer cells. This evidence concerns the gene TP53 and breast cancer.